drugset / Trial / NCT01541852
Losmapimod in Chronic Obstructive Pulmonary Disease Patients Stratified by Fibrinogen.
Phase 2
Completed
72 enrolled
Cambridge University Hospitals NHS Foundation Trust
GlaxoSmithKline · collabRoyal Brompton & Harefield NHS Foundation Trust · collabTechnology Strategy Board, United Kingdom · collabUniversity of Cambridge · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
The main purpose of this study is to determine the effect of Losmapimod on blood vessels in patients with Chronic Obstructive Pulmonary Disease (COPD). Although COPD is a lung disease, it is also associated with an increased risk of cardiovascular disease (e.g. heart attacks and stroke). The investigators believe that this is a result of inflammation within the body, which damages the lining (endothelium) and walls of blood vessels. These changes can promote the development of fatty deposits within the walls of arteries (atherosclerosis) which can rupture and block arteries causing damage.
Timeline
- Start
- 2012-06
- Primary completion
- 2014-02
- Completion
- 2014-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Losmapimod | Small molecule | 7.5 mg | — |